Cadila Pharmaceuticals and Wellesta Holdings have signed a memorandum of understanding to establish a strategic joint venture focused on commercialising pharmaceutical and healthcare products across South-East Asia and selected international markets.

• Core Focus: The proposed joint venture will identify and commercialise pharmaceutical and healthcare products by combining Cadila’s product development and manufacturing capabilities with Wellesta’s commercial and market expertise.
• Market Expansion: The collaboration is intended to support expansion across South-East Asia, the Middle East, Africa and other emerging markets.
• Operational Objective: The partnership aims to strengthen Cadila’s presence in key growth markets while expanding Wellesta’s healthcare product portfolio.

This summary is based on a news article published by BioSpectrum Asia.

Image for illustrative purposes only. Source: Canva.

About Ehub365

For Corporate Clients, ehub365 division delivers critical insights into the ASEAN medical sector, covering investments, new services, and practitioner news. 

A member of 365Asia. Our additional group services are Health365, 365Asia, 健康365, 365Sehat, and 365MEC.